2019
Anti-Müllerian Hormone and its Predictive Utility in Assisted Reproductive Technologies Outcomes
GRANGER E, TAL R. Anti-Müllerian Hormone and its Predictive Utility in Assisted Reproductive Technologies Outcomes. Clinical Obstetrics & Gynecology 2019, Publish Ahead of Print: &na;. DOI: 10.1097/grf.0000000000000436.Peer-Reviewed Original ResearchAnti-Müllerian hormoneART outcomesOvarian responseAssisted Reproductive Technology OutcomesControlled ovarian stimulationReproductive technology outcomesInformative biochemical markersHyperstimulation risksOvarian stimulationClinical utilitySensitive markerStimulation protocolBiochemical markersReproductive agingTechnology outcomesOutcomesHormonePredictive utilityBest predictorMarkersResponseChapter 25 The Role of Antimullerian Hormone in Assisted Reproduction
Tal R, Seifer D. Chapter 25 The Role of Antimullerian Hormone in Assisted Reproduction. 2019, 403-414. DOI: 10.1016/b978-0-12-813209-8.00025-x.ChaptersAntimullerian hormoneOvarian responseControlled ovarian stimulationOnset of menopausePrimordial follicle poolInformative biochemical markersOvarian stimulationOvarian reserveFertility preservationAbnormal folliculogenesisFollicle poolClinical utilityParacrine regulatorSensitive markerStimulation protocolChronologic ageOvarian folliclesGranulosa cellsBiochemical markersReproductive agingReproductive medicineInverse correlationAssisted reproductionReproductive technologiesClinical application
2017
Ovarian reserve testing: a user’s guide
Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. American Journal Of Obstetrics And Gynecology 2017, 217: 129-140. PMID: 28235465, DOI: 10.1016/j.ajog.2017.02.027.Peer-Reviewed Original ResearchConceptsOvarian reserve testingOvarian reserve testsOvarian reserveAntimüllerian hormoneDay 3 follicle-stimulating hormonePolycystic ovary syndromeFemale cancer patientsFollicle-stimulating hormoneFertility treatment optionsSelection of treatmentAntral follicular countAge-specific valuesGood predictive valueComplex clinical phenomenonOvarian hyperstimulationOvarian stimulationOvary syndromeGonadotoxic therapyTreatment optionsCancer patientsPoor responseReproductive ageFollicular countReproductive endocrinologistsTreatment protocol
2014
Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2013
Angiopoietin-2 is increased in follicular fluid of polycystic ovarian syndrome (PCOS) women during controlled ovarian stimulation and correlates with number of oocytes retrieved
Tal R, Seifer D, Shohat-Tal A, Malter H, Grazi R. Angiopoietin-2 is increased in follicular fluid of polycystic ovarian syndrome (PCOS) women during controlled ovarian stimulation and correlates with number of oocytes retrieved. Fertility And Sterility 2013, 100: s360. DOI: 10.1016/j.fertnstert.2013.07.851.Peer-Reviewed Original ResearchTransforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation
Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE. Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. Fertility And Sterility 2013, 100: 538-543. PMID: 23684116, DOI: 10.1016/j.fertnstert.2013.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CDCase-Control StudiesEndoglinFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromeReceptors, Cell SurfaceSperm Injections, IntracytoplasmicTransforming Growth Factor beta1UltrasonographyYoung AdultConceptsPolycystic ovarian syndromeSerum soluble endoglinDay of hCGSoluble endoglinFollicular fluidTGF-β1Oocyte retrievalOvarian stimulationHCG administrationControl womenDay 3Pathogenesis of PCOSNon-PCOS control groupProspective case-control studyNon-PCOS controlsSerum TGF-β1Non-PCOS womenPolycystic ovary syndromeTGF-β1 levelsReproductive technology unitCase-control studyGrowth factor-β1Day of retrievalOvarian hyperstimulationOvarian syndrome
2012
Preeclampsia-associated soluble endoglin (sENG) is decreased in polycystic ovarian syndrome (PCOS) leading to transforming growth factor (TGF)-B1 dysregulation during controlled ovarian stimulation
Tal R, Seifer D, Shohat-Tal A, Grazi R, Malter H. Preeclampsia-associated soluble endoglin (sENG) is decreased in polycystic ovarian syndrome (PCOS) leading to transforming growth factor (TGF)-B1 dysregulation during controlled ovarian stimulation. Fertility And Sterility 2012, 98: s84. DOI: 10.1016/j.fertnstert.2012.07.304.Peer-Reviewed Original Research